Please note that any funds granted from the FSHD Canada Foundation cannot be used to cover more than ten percent (10%) of overhead costs.
Generation of porcine large animal models for FSHD therapeutic development and preclinical testing
Investigators: Peter L. Jones Lab; University of Nevada, Reno School of Medicine The primary therapeutic target in all forms of FSHD is DUX4-fl mRNA and DUX4-FL protein, and animal models…
Read MoreMotor Outcomes to Validate Evaluations in FSHD
Investigators: Jeffrey Statland, PI (University of Kansas Medical Center); and Rabi Tawil, Co-PI (University of Rochester Medical Center) The primary goal of this proposal is to hasten therapeutic development for…
Read MoreFacio Therapies
Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4.…
Read MoreMouse Model to Validate Drugs Targeting DUX4 Enhancer/Promoter Activity
Investigator: Yosuke Hiramuki, Ph.D. at the University of Nevada, Reno We created a mouse model to validate the effect of drugs targeting DUX4 gene expression in a whole living organism.…
Read MoreTesting the efficacy of CRISPRi in FSHD2
Investigators: Takako Jones, PhD and Charis L. Himeda, PhD; University of Nevada, Reno School of Medicine The goal of this proposal is to test the utility of our CRISPR inhibition…
Read MoreAll-in-one CRISPR inhibition for FSHD1 and FSHD2
Investigator: Charis L. Himeda, PhD, Research Assistant Professor Research Institution: Peter Jones Lab, University of Nevada, Reno School of Medicine, Reno NV USA The most direct path to an FSHD…
Read More